$GOVX
GeoVax Labs, Inc.

2019 Q3 Form 10-Q Financial Statement

#000143774919016606 Filed on August 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2
Revenue $333.2K $209.9K $93.27K
YoY Change -4.62% 125.1% -73.51%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $290.0K $410.0K $360.0K
YoY Change -36.96% 13.89% 2.86%
% of Gross Profit
Research & Development $467.7K $451.2K $372.2K
YoY Change -16.14% 21.23% -28.16%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00 $10.00K
YoY Change -100.0%
% of Gross Profit
Operating Expenses $759.1K $863.9K $731.4K
YoY Change -25.33% 18.11% -15.96%
Operating Profit -$425.9K -$653.9K -$638.1K
YoY Change -36.17% 2.48% 23.16%
Interest Expense $1.054K $1.093K $625.00
YoY Change 68.64% 74.88%
% of Operating Profit
Other Income/Expense, Net $1.506K -$212.00 $1.091K
YoY Change 247.81% -119.43% -14.16%
Pretax Income -$420.0K -$650.0K -$640.0K
YoY Change -37.31% 1.56% 23.08%
Income Tax
% Of Pretax Income
Net Earnings -$424.4K -$654.1K -$637.0K
YoY Change -36.36% 2.69% 23.25%
Net Earnings / Revenue -127.38% -311.59% -683.05%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.302B -$40.29B -$82.09B
COMMON SHARES
Basic Shares Outstanding 2.478M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $570.0K $220.0K $190.0K
YoY Change 11.76% 15.79% -76.83%
Cash & Equivalents $569.4K $216.4K $191.0K
Short-Term Investments
Other Short-Term Assets $120.0K $40.00K $150.0K
YoY Change 71.43% -73.33% 400.0%
Inventory
Prepaid Expenses
Receivables $100.0K $60.00K $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $795.6K $319.8K $339.1K
YoY Change 33.45% -5.71% -63.67%
LONG-TERM ASSETS
Property, Plant & Equipment $9.929K $11.83K $21.22K
YoY Change -38.97% -44.27% -53.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $20.94K $22.84K $32.23K
YoY Change -23.24% -29.15% -42.84%
TOTAL ASSETS
Total Short-Term Assets $795.6K $319.8K $339.1K
Total Long-Term Assets $20.94K $22.84K $32.23K
Total Assets $816.5K $342.6K $371.4K
YoY Change 30.97% -7.74% -62.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $63.14K $116.2K $66.03K
YoY Change -57.32% 75.99% -56.54%
Accrued Expenses $1.732M $1.510M $998.1K
YoY Change 50.68% 51.32% 99.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K $0.00
YoY Change 0.0%
Total Short-Term Liabilities $1.808M $1.639M $1.068M
YoY Change 38.55% 53.42% 63.95%
LONG-TERM LIABILITIES
Long-Term Debt $30.00K $30.00K $50.00K
YoY Change -25.0% -40.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $30.00K $30.00K $50.00K
YoY Change -25.0% -40.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.808M $1.639M $1.068M
Total Long-Term Liabilities $30.00K $30.00K $50.00K
Total Liabilities $1.837M $1.671M $1.114M
YoY Change 36.32% 50.01% 71.4%
SHAREHOLDERS EQUITY
Retained Earnings -$42.26M -$41.83M -$39.18M
YoY Change 6.06% 6.78% 6.42%
Common Stock $38.91M $38.17M $36.72M
YoY Change 5.15% 3.93% 4.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.021M -$1.329M -$742.7K
YoY Change
Total Liabilities & Shareholders Equity $816.5K $342.6K $371.4K
YoY Change 30.97% -7.74% -62.49%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$424.4K -$654.1K -$637.0K
YoY Change -36.36% 2.69% 23.25%
Depreciation, Depletion And Amortization $10.00K $0.00 $10.00K
YoY Change -100.0%
Cash From Operating Activities -$350.0K -$450.0K -$380.0K
YoY Change 25.0% 18.42% -11.63%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 700.0K 490.0K 0.000
YoY Change 16.67% -100.0%
NET CHANGE
Cash From Operating Activities -350.0K -450.0K -380.0K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 700.0K 490.0K 0.000
Net Change In Cash 350.0K 40.00K -380.0K
YoY Change 9.37% -110.53% -158.46%
FREE CASH FLOW
Cash From Operating Activities -$350.0K -$450.0K -$380.0K
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$350.0K -$450.0K -$380.0K
YoY Change 25.0% 18.42% -11.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1510268
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Trading Symbol
TradingSymbol
govx
CY2019Q2 govx Accrued Directors Fees Current
AccruedDirectorsFeesCurrent
361470
CY2018Q4 govx Accrued Directors Fees Current
AccruedDirectorsFeesCurrent
295670
CY2019Q2 govx Stock Issued During Period Value Expensed During The Period Issued For Services
StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices
78509
govx Stock Issued During Period Value Expensed During The Period Issued For Services
StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices
205080
CY2018Q2 govx Stock Issued During Period Value Expensed During The Period Issued For Services
StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices
57143
govx Stock Issued During Period Value Expensed During The Period Issued For Services
StockIssuedDuringPeriodValueExpensedDuringThePeriodIssuedForServices
85714
CY2019Q1 govx Stock Issued During Period Value Reverse Stock Splits Fractional Shares
StockIssuedDuringPeriodValueReverseStockSplitsFractionalShares
CY2019Q2 govx Stock Issued During Period Value Reverse Stock Splits Fractional Shares
StockIssuedDuringPeriodValueReverseStockSplitsFractionalShares
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
116207
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
125859
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1238552
CY2019Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1128425
CY2018Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
924509
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
667041
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
663246
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
38165172
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
37482766
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26652
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26664
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23978
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2477584
dei Security12b Title
Security12bTitle
Common Stock
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23221
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
581793
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
51270
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
51155
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
497098
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26664
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
53316
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23221
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47199
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
376130
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
351684
CY2019Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
8400
CY2019Q2 us-gaap Assets
Assets
342633
CY2018Q4 us-gaap Assets
Assets
642064
CY2019Q2 us-gaap Assets Current
AssetsCurrent
319796
CY2018Q4 us-gaap Assets Current
AssetsCurrent
619704
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis of Presentation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying condensed consolidated financial statements at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Interim results are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018. </div>We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be relied upon as predictive of the results in future periods.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As described in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,</div> effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 30, 2019, </div>we enacted a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five hundred</div> reverse stock split of our common stock. The accompanying financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock split.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period following the date of the financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine candidates. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue these activities.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe that our existing cash resources, government funding commitments, and equity funding commitments discussed in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div> will be sufficient to continue our planned operations into the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div> Due to our history of operating losses and our continuing need for capital to conduct our research and development activities, there is substantial doubt concerning our ability to operate as a going concern beyond that date. We are currently exploring sources of capital through additional government grants and corporate collaborations. We also intend to secure additional funds through sales of our equity securities or by other means. Management believes that we will be successful in securing the additional capital required to continue the Company&#x2019;s planned operations, but that our plans do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> fully alleviate the substantial doubt about the Company&#x2019;s ability to operate as a going concern. Additional funding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be available on favorable terms or at all. If we fail to obtain additional capital when needed, we will be required to delay, scale back, or eliminate some or all of our research and development programs as well as reduce our general and administrative expenses.</div></div>
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
259701
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
312727
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
216411
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190969
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-43290
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-121758
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
813916
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
437807
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
813916
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
437807
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
814
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
438
CY2019Q2 us-gaap Deposits Assets
DepositsAssets
11010
CY2018Q4 us-gaap Deposits Assets
DepositsAssets
11010
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3795
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9930
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.01
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.05
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
157067
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y328D
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
412650
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
359197
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1624831
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.50
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
922714
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
716425
CY2019Q2 us-gaap Grants Receivable
GrantsReceivable
64246
CY2018Q4 us-gaap Grants Receivable
GrantsReceivable
121814
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
262064
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
252802
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
30
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-41695
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-57568
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-59758
CY2019Q2 us-gaap Interest Expense
InterestExpense
1093
CY2018Q2 us-gaap Interest Expense
InterestExpense
625
us-gaap Interest Expense
InterestExpense
2221
us-gaap Interest Expense
InterestExpense
833
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
881
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1716
us-gaap Investment Income Interest
InvestmentIncomeInterest
2105
us-gaap Investment Income Interest
InvestmentIncomeInterest
3034
CY2019Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
40316
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
80633
CY2018Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
39136
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
78273
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
80633
CY2019Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2019Q2 us-gaap Liabilities
Liabilities
1671266
CY2018Q4 us-gaap Liabilities
Liabilities
1664411
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
342633
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
642064
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1638975
CY2019Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
32291
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
50000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
674596
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11827
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11350
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5209
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
451227
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
863877
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
859196
CY2018Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
39580
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Description of Business </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases using a novel vector vaccine platform (Modified Vaccinia Ankara Virus-Like Particle, or &#x201c;MVA-VLP&#x201d;). Our recombinant MVA vector expresses target proteins on highly immunogenic VLPs in the person being vaccinated, resulting in durable immune responses while providing the safety characteristics of the replication-defective MVA vector. Important attributes of GeoVax vaccines include single dose, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> adjuvant, durable immunity, extensive safety and cost-effective manufacturing.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our current development programs are focused on preventive and therapeutic vaccines against Human Immunodeficiency Virus (HIV); preventive vaccines against hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa fever), Zika virus and malaria; a therapeutic vaccine for chronic hepatitis B virus infections; and preventive and therapeutic vaccines for multiple solid tumor cancers. Our most advanced vaccine program is focused on the clade B subtype of HIV prevalent in the larger commercial markets of the Americas, Western Europe, Japan and Australia; this program is currently undergoing human clinical trials.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our corporate strategy is to improve health to patients worldwide by advancing our vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>take many years and often involves expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more potential strategic partners.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in metropolitan Atlanta, Georgia.</div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
734791
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
640000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4272
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-773809
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-761758
us-gaap Net Income Loss
NetIncomeLoss
-1355602
us-gaap Net Income Loss
NetIncomeLoss
-1258856
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-654148
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-637043
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-701454
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-621813
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-212
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1091
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-116
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2201
CY2019Q2 us-gaap Notes Payable Current
NotesPayableCurrent
12500
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
260420
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
731399
us-gaap Operating Expenses
OperatingExpenses
1929659
us-gaap Operating Expenses
OperatingExpenses
1575621
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-653936
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-638134
us-gaap Operating Income Loss
OperatingIncomeLoss
-1355486
us-gaap Operating Income Loss
OperatingIncomeLoss
-1261057
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
20373
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18373
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4272
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3402
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3450
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3402
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3450
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
2337867
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
1971333
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
39139
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
238189
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
740000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
590000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41832486
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40476884
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
209941
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
678868
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
372202
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1006945
CY2018Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
93265
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
574173
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
314564
us-gaap Share Based Compensation
ShareBasedCompensation
258396
us-gaap Share Based Compensation
ShareBasedCompensation
132913
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
13585
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
93.92
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
29441
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
53.19
CY2019Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
4127
CY2018Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
0
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
10000
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
4127
CY2019Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2018Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2018Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2019Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
6000
CY2018Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
200000
CY2019Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
490000
CY2019Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
500000
CY2018Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
590000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-1328633
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1022347
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-1207149
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-321057
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-128892
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-742714
CY2019Q2 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
459000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
649486
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
310419
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
571032
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
279551

Files In Submission

Name View Source Status
0001437749-19-016606-index-headers.html Edgar Link pending
0001437749-19-016606-index.html Edgar Link pending
0001437749-19-016606.txt Edgar Link pending
0001437749-19-016606-xbrl.zip Edgar Link pending
ex_153740.htm Edgar Link pending
ex_153741.htm Edgar Link pending
ex_153742.htm Edgar Link pending
ex_153743.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
govx-20190630.xml Edgar Link completed
govx-20190630.xsd Edgar Link pending
govx-20190630_cal.xml Edgar Link unprocessable
govx-20190630_def.xml Edgar Link unprocessable
govx-20190630_lab.xml Edgar Link unprocessable
govx-20190630_pre.xml Edgar Link unprocessable
govx20190630_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending